NURO · Neurometrix, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | $275.4K | $277.2K | $576.5K | - | $421.4K | $536.5K | $526.4K | - | $693.6K |
| Gross Profit | - | $312.0K | $491.9K | $517.0K | - | $781.8K | $1.12M | $1.20M | - | $1.27M |
| R&D | - | $299.7K | $266.9K | $943.6K | - | $592.7K | $753.5K | $699.4K | - | $1.07M |
| SG&A | - | $1.31M | $1.62M | $1.77M | - | $1.21M | $1.24M | $1.39M | - | $1.10M |
| Total Operating Expenses | - | $2.05M | $2.32M | $3.77M | - | $2.74M | $2.74M | $2.91M | - | $2.99M |
| D&A | - | - | - | $24.9K | - | - | - | $10.2K | - | - |
| Operating Income | - | ($1.74M) | ($1.83M) | ($3.25M) | - | ($1.96M) | ($1.62M) | ($1.71M) | - | ($1.71M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($1.51M) | ($1.49M) | ($3.03M) | - | ($1.77M) | ($1.54M) | ($1.57M) | - | ($1.61M) |
| EPS - Basic | - | ($0.75) | ($0.74) | ($1.67) | - | ($0.21) | ($0.19) | ($0.20) | - | ($0.23) |
| EPS - Diluted | - | ($0.75) | ($0.74) | ($1.67) | - | ($0.21) | ($0.19) | ($0.20) | - | ($0.23) |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.43M | $921.5K | $1.61M | $1.26M | $1.73M | $1.46M | $1.86M | $2.38M | $4.25M | $1.77M |
| Accounts Receivable | $192.9K | $149.1K | $280.6K | $469.6K | $518.8K | $614.4K | $746.7K | $576.3K | $646.8K | $702.5K |
| Inventory | $1.35M | $1.43M | $1.45M | $1.47M | $1.56M | $1.67M | $1.58M | $1.75M | $1.61M | $1.06M |
| Accounts Payable | $363.3K | $347.6K | $314.0K | $144.6K | $215.5K | $225.5K | $181.5K | $400.3K | $368.1K | $539.4K |
| Current Assets | $15.01M | $16.80M | $18.48M | $20.15M | $20.85M | $20.71M | $22.29M | $23.09M | $24.11M | $23.43M |
| Total Assets | $15.32M | $17.19M | $18.93M | $20.66M | $21.42M | $21.29M | $22.77M | $23.61M | $24.67M | $24.03M |
| Current Liabilities | $1.01M | $1.21M | $1.59M | $1.85M | $1.24M | $1.26M | $1.21M | $1.42M | $1.11M | $1.83M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.01M | $1.21M | $1.62M | $1.91M | $1.33M | $1.38M | $1.36M | $1.60M | $1.31M | $2.07M |
| Stockholders' Equity | $14.31M | $15.98M | $17.31M | $18.76M | $20.09M | $19.90M | $21.41M | $22.01M | $23.36M | $21.97M |
| Retained Earnings | ($217.92M) | ($216.14M) | ($214.63M) | ($213.14M) | ($210.11M) | ($208.46M) | ($206.69M) | ($205.15M) | ($203.58M) | ($202.89M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($2.08M) | - | - | - | ($1.12M) | - | - |
| Investing Cash Flow | - | - | - | $138.3K | - | - | - | ($837.0K) | - | - |
| Financing Cash Flow | - | - | - | $1.47M | - | - | - | $0 | - | - |
| CapEx | - | - | - | - | - | - | - | $0 | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($1.12M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 0.71 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -8.8% | -7.9% | -14.7% | - | -8.3% | -6.7% | -6.7% | - | -6.7% |
| Return on equity | - | -9.4% | -8.6% | -16.2% | - | -8.9% | -7.2% | -7.2% | - | -7.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.83 | 13.88 | 11.62 | 10.91 | 16.81 | 16.43 | 18.42 | 16.29 | 21.79 | 12.79 |
| Quick ratio | 13.50 | 12.70 | 10.71 | 10.11 | 15.55 | 15.11 | 17.11 | 15.06 | 20.33 | 12.21 |
| Cash ratio | 1.41 | 0.76 | 1.01 | 0.68 | 1.40 | 1.16 | 1.54 | 1.68 | 3.84 | 0.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.07 | 1.08 | 1.09 | 1.10 | 1.07 | 1.07 | 1.06 | 1.07 | 1.06 | 1.09 |
| Liabilities / Assets | 0.07 | 0.07 | 0.09 | 0.09 | 0.06 | 0.06 | 0.06 | 0.07 | 0.05 | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | 0.19 | 0.19 | 0.39 | - | 0.25 | 0.34 | 0.30 | - | 0.66 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | 1896d | 1910d | 932d | - | 1444d | 1078d | 1212d | - | 556d |
| Days payable outstanding | - | 461d | 413d | 92d | - | 195d | 123d | 278d | - | 284d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -60.1% | -56.0% | -56.9% | - | -38.7% | -22.9% | -33.2% | - | -11.8% |
| Operating income growth (YoY) | - | 11.2% | -12.6% | -90.3% | - | -14.5% | -34.1% | -77.8% | - | -149.0% |
| Net income growth (YoY) | - | 14.7% | 3.2% | -92.5% | - | -10.1% | -32.5% | -64.2% | - | -133.8% |
| EPS growth (YoY) | - | -257.1% | -289.5% | -735.0% | - | 8.7% | -11.8% | -900.0% | - | -91.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | -50.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -28.8% | -19.7% | -19.1% | -14.8% | -14.0% | -9.4% | -8.5% | -9.2% | 0.6% | -9.3% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing NeuroMetrix against the 5 most active filers in the same SIC group.